This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis

Read More: Endeavor BioMedicines                                                                         

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Read More: Vicore                                                                                                         

GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma

Read More: GSK                                                                                                      

Sanofi Highlights Data from the P-III (NOTUS) Study of Dupixent for COPD at ATS 2024 and Publishes in the NEJM

Read More: Sanofi                                                                                                      

Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024

Read More: Sanofi                                                                                                          

Eupraxia Pharmaceuticals Reports EP-104GI’s P-Ib/2a (RESOLVE) Study Expansion to Treat Eosinophilic Esophagitis (EoE)

Read More: Eupraxia Pharmaceuticals                                                                   

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

Read More: Laekna                                                                                                     

IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy

Read More: IRLAB                 

HI-Bio Presents Positive Interim Data from P-II (IGNAZ) Trial of Felzartamab for IgA at 61st ERA Congress 2024

Read More: HI-Bio                                                                                  

Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired and Ventilator-Associated Pneumonia

Read More: Zai Lab & Innoviva                                                                                

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer

Read More: MediciNova                                                                                         

Roche’s Inavolisib Receives the US FDA’s Breakthrough Therapy Designation for Breast Cancer

Read More: Roche                                                                                                    

Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease

Read More: Innovent                                                                                              

BMS Reports the US FDA’s Updated Action Date for Subcutaneous Opdivo (Nivolumab and Hyaluronidase)

Read More: BMS                                                                                                      

Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals

Read More: Aktis Oncology & Eli Lilly                                                                   

Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s RMAT Designation to Treat Myasthenia Gravis

Read More: Cartesian Therapeutics                                                                      

The US FDA Grants Fast Track Designation to Theriva Biologics’ VCN-01 as 1L Treatment of PDAC

Read More: Theriva Biologics                                                                                   

Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

Read More: Shanghai Henlius & Organon                                                   

Boston Scientific Corporation Highlights 6 Months Data of MODULAR ATP Study & 5 Years Data of APPRAISE ATP Study at Heart Rhythm 2024

Read More: Boston Scientific                                                                                    

Roche’s Blood Test to Measure Lp(a) Receives the US FDA’s Breakthrough Device Designation, Enhancing its Cardiovascular Portfolio

Read More: Roche                                                                                         

The US FDA Clears Indica Labs’ HALO AP Dx Digital Pathology Platform

Read More: Indica Labs                                                                                          

Fractyl Health Highlights the Preclinical Data of its Pancreatic Gene Therapy at DDW 2024

Read More: Fractyl Health                                                                                        

Biocon’s Yesafili (Biosimilar, Eylea) Receives the US FDA’s Approval for Ophthalmology

Read More: Biocon                                                                                                     

Sandoz Reports EC’s Approval of Wyost and Jubbonti (Biosimilars, Xgeva and Prolia)

Read More: Sandoz                                                                                                    

Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM) Diseases

Read More: Boehringer Ingelheim & OSE Immunotherapeutics                      

Cytokinetics Expands its Funding Collaboration with Royalty Pharma to Commercialize Aficamten and Advance R&D Pipeline

Read More: Cytokinetics & Royalty Pharma                                                        

Swixx Biopharma Acquires Biopas, Expanding its Presence to Latin America

Read More: Swixx Biopharma & Biopas                                                              

For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

Read More: Biogen & Human Immunology Biosciences                                   

Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

Read More: Merck KGaA & Mirus Bio                                                                   

Orna Therapeutics Acquires ReNAgade for Circular RNA Therapies

Read More: Orna Therapeutics & ReNAgade                       

Related Post: PharmaShots Weekly Snapshots (May 13 – May 17, 2024)